An observational study in Iron Induced Hypophosphatemia, sponsored by University Hospital, Geneva. Completed at 1 site in Switzerland. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-30.
Sponsored by University Hospital, Geneva · Observational
Iron deficiency anemia (IDA) is a very common health problem during pregnancy and intravenous (IV) iron substitution has become part of routine management. Recent studies have raised concerns about association of IV iron infusion and development of secondary transitory hypophosphatemia (HP) in adults including pregnant women. The study aimed to evaluate the impact of IV iron administration during pregnancy on newborn's phosphatemia.
The investigators conducted a prospective, single-center, observational study in the Geneva University Hospitals (HUG), from September 2022 to March 2023. Pregnant women treated either with IV iron or with oral iron during pregnancy were included. At delivery, a maternal blood sample to assess hemoglobin, hematocrit, ferritin, phosphate and calcium and an umbilical cord blood sample to assess levels of phosphate and calcium were collected. Difference in demographics and clinical characteristics between the two groups were explored using univariate analyses. Multivariate analyses were performed to test the contribution of IV iron substitution on cord blood phosphatemia and calcemia, considering potential confounding factors. Neonatal HP was defined as a phosphate level lower than 1.3 mmol/L.
53 studies on the registry are indexed under Hypophosphatemia; 16 are open to participants now.
This study's enrollment of 43 is below the median of 105 across 26 observational studies indexed under Hypophosphatemia.
Browse Hypophosphatemia studies →University Hospital, Geneva is the lead sponsor of 379 studies on the registry; 70 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Women with an uncomplicated term (≥ 37 weeks) single pregnancy who received IV iron or oral iron substitution from the 2nd trimester of pregnancy (>12 weeks of pregnancy) to the day of delivery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: IV iron administration
IV iron administration during pregnancy
Concentration of cord blood phosphate in neonates
Time frame: Single timepoint at delivery
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2022 to primary completion in Mar 2023, 5 months.
Of 14 observational studies under Hypophosphatemia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.